Status:
COMPLETED
Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer
Lead Sponsor:
Michael Patrick Achiam
Conditions:
Esophagus Cancer, Adenocarcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The aim of this study is to investigate urokinase Plasminogen Activator Receptor (uPAR) microexpression in gastroesophageal cancer (adenocarcinomas) both qualitatively and semi-quantitatively and to e...
Detailed Description
* Sections of the tumor tissue will be HE stained. * Sections of the tumor tissue will be stained with an uPAR antibody for immunohistochemistry. * Immunohistochemical staining against cytokeratin whi...
Eligibility Criteria
Inclusion
- Age ≥18 years old.
- Patients who underwent curatively intended surgery for gastroesophageal cancer
- Patients who underwent surgery after 01-01-2016.
Exclusion
- Patients who applied for an exception from medical research at the "National Registry of Tissue Use."
- Patients with other histological subtypes than adenocarcinoma.
Key Trial Info
Start Date :
November 18 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04669951
Start Date
November 18 2019
End Date
November 30 2020
Last Update
June 3 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet
Copenhagen, Capital Region, Denmark, 2100